Discovery of potent bruton’s tyrosine kinase inhibitors using ligand based modeling

Anti-Cancer Agents in Medicinal Chemistry

Volumn 17, Issue 2, 2017, Pages 265-275

  Mera, Wafa A ^a   Alzihlif, Malek ^a   Taha, Mutasem O ^a   Khanfar, Mohammad A ^a,b  

^a UNIVERSITY OF JORDAN   (Jordan)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Anticancer; BTK; Multiple linear regression; Pharmacophore; QSAR

Indexed keywords

ANTINEOPLASTIC AGENT; BRUTON TYROSINE KINASE INHIBITOR; ENZYME INHIBITOR; LIGAND; STREPTOMYCIN; AGAMMAGLOBULINAEMIA TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CELL CULTURE; CELL MATURATION; CELL PROLIFERATION ASSAY; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME ACTIVATION; FIBROBLAST CULTURE; GENETIC MANIPULATION; HUMAN; HUMAN CELL; IC50; LEUKEMIA; MTT ASSAY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; PHYSICOCHEMICAL MODEL; STRUCTURE ACTIVITY RELATION; ALGORITHM; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; LYMPHOMA; METABOLISM; MOLECULAR MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; TUMOR CELL LINE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; HUMANS; LEUKEMIA; LIGANDS; LINEAR MODELS; LYMPHOMA; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; ROC CURVE;

EID: 85011039453     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520616666160926114416     Document Type: Article

References (20)

1. Satterthwaite, A.B.; Witte, O.N. The role of Bruton's tyrosine kinase in B-cell development and function: A genetic perspective. Immunol. Rev., 2000, 175, 120-127.
2. Buggy, J.J.; Elias, L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int. Rev. Immunol., 2012, 31(2), 119-132.
3. Honigberg, L.A.; Smith, A.M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D.H.; Miller, R.A.; Buggy, J.J. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. USA, 2010, 107(29), 13075-13080.
4. Rushworth, S.A.; Murray, M.Y.; Zaitseva, L.; Bowles, K.M.; MacEwan, D.J. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood, 2014, 123(8), 1229-1238.
5. Pan, Z.; Scheerens, H.; Li, S.J.; Schultz, B.E.; Sprengeler, P.A.; Burrill, L.C.; Mendonca, R.V.; Sweeney, M.D.; Scott, K.C.; Grothaus, P.G.; Jeffery, D.A.; Spoerke, J.M.; Honigberg, L. A.; Young, P.R.; Dalrymple, S.A.; Palmer, J.T. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem. Med. Chem., 2007, 2(1), 58-61.
6. Byrd, J.C.; Harrington, B.; O'Brien, S.; Jones, J.A.; Schuh, A.; Devereux, S.; Chaves, J.; Wierda, W.G.; Awan, F.T.; Brown, J.R.; Hillmen, P.; Stephens, D.M.; Ghia, P.; Barrientos, J.C.; Pagel, J.M.; Woyach, J.; Johnson, D.; Huang, J.; Wang, X.; Kaptein, A.; Lannutti, B.J.; Covey, T.; Fardis, M.; McGreivy, J.; Hamdy, A.; Rothbaum, W.; Izumi, R.; Diacovo, T.G.; Johnson, A. J.; Furman, R.R. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med., 2016, 374(4), 323-332.
7. Lavecchia, A.; Di Giovanni, C. Virtual screening strategies in drug discovery: A critical review. Curr. Med. Chem., 2013, 20(23), 2839-2860.
8. Khanfar, M.A.; Taha, M.O. Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors. J. Chem. Inf. Model, 2013, 53(10), 2587-2612.
9. Taha, M.O.; Al-Sha'er, M.A.; Khanfar, M.A.; Al-Nadaf, A.H. Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis. Eur. J. Med. Chem., 2014, 84, 454-465.
10. Taha, M.O.; Habash, M.; Khanfar, M.A. The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators. J. Comput. Aided Mol. Des., 2014, 28(5), 509-547.
11. Al-Sha'er, M.A.; Khanfar, M.A.; Taha, M.O. Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand- based modeling and virtual screening followed by in vitro analysis. J. Mol. Model, 2014, 20(1), 2080.
12. Shi, Q.; Tebben, A.; Dyckman, A.J.; Li, H.; Liu, C.; Lin, J.; Spergel, S.; Burke, J.R.; McIntyre, K.W.; Olini, G.C.; Strnad, J.; Surti, N.; Muckelbauer, J.K.; Chang, C.; An, Y.; Cheng, L.; Ruan, Q.; Leftheris, K.; Carter, P.H.; Tino, J.; De Lucca, G.V. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases. Bioorg. Med. Chem. Lett., 2014, 24(9), 2206-2211.
13. Rogers, D.; Hopfinger, A.J. Application of genetic function approximation to quantitative structure-activity-relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci., 1994, 34(4), 854-866.
14. Verdonk, M.L.; Berdini, V.; Hartshorn, M.J.; Mooij, W.T.; Murray, C.W.; Taylor, R.D.; Watson, P. Virtual screening using protein-ligand docking: Avoiding artificial enrichment. J. Chem. Inf. Comput Sci., 2004, 44(3), 793-806.
15. Sundstrom, C.; Nilsson, K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer, 1976, 17(5), 565-577.
16. Chang, C.E.; Chen, W.; Gilson, M.K. Ligand configurational entropy and protein binding. Proc. Natl. Acad. Sci. USA, 2007, 104(5), 1534-159.
17. Rankin, A.L.; Seth, N.; Keegan, S.; Andreyeva, T.; Cook, T.A.; Edmonds, J.; Mathialagan, N.; Benson, M.J.; Syed, J.; Zhan, Y.; Benoit, S.E.; Miyashiro, J.S.; Wood, N.; Mohan, S.; Peeva, E.; Ramaiah, S.K.; Messing, D.; Homer, B.L.; Dunussi-Joannopoulos, K.; Nickerson-Nutter, C.L.; Schnute, M.E.; Douhan, J.3rd. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J. Immunol., 2013, 191(9), 4540-4550.
18. Shoichet, B.K. Interpreting steep dose-response curves in early inhibitor discovery. J. Med. Chem., 2006, 49(25), 7274-7.
19. Li, X.; Zuo, Y.; Tang, G.; Wang, Y.; Zhou, Y.; Wang, X.; Guo, T.; Xia, M.; Ding, N.; Pan, Z. Discovery of a series of 2,5- diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J. Med. Chem., 2014, 57(12), 5112-5128.
20. Afar, D.E.; Park, H.; Howell, B.W.; Rawlings, D.J.; Cooper, J.; Witte, O.N. Regulation of Btk by Src family tyrosine kinases. Mol. Cell Biol., 1996, 16(7), 3465-3471.